Deep dive into the immune response against murine mesothelioma permits design of novel anti-mesothelioma therapeutics - Université de Paris - Faculté de Santé Accéder directement au contenu
Article Dans Une Revue Frontiers in Immunology Année : 2023

Deep dive into the immune response against murine mesothelioma permits design of novel anti-mesothelioma therapeutics

Résumé

Given the need to improve the efficacy of standard-of-care immunotherapy (anti-CTLA-4 + anti-PD-1) in human malignant pleural mesothelioma (hMPM), we thoroughly characterized the immunobiology of the AB12 murine mesothelioma (MM) model, aiming to increase its accuracy in predicting the response of hMPM to immunotherapy and in designing novel anti-hMPM treatments. Specifically, we used immunologic, transcriptomic and survival analyses, to synchronize the MM tumor growth phases and immune evolution with the histo-molecular and immunological characteristics of hMPM while also determining the anti-MM efficacy of standard-of-care anti-hMPM immunotherapy as a benchmark that novel therapeutics should meet. We report that early-, intermediate- and advanced- AB12 tumors are characterized by a bell-shaped anti-tumor response that peaks in intermediate tumors and decays in advanced tumors. We further show that intermediate- and advanced- tumors match with immune active (“hot”) and immune inactive (“cold”) hMPM respectively, and that they respond to immunotherapy in a manner that corresponds well with its performance in real-life settings. Finally, we show that in advanced tumors, addition of cisplatin to anti CTLA-4 + anti PD-1 can extend mice survival and invigorate the decaying anti-tumor response. Therefore, we highlight this triple combination as a worthy candidate to improve clinical outcomes in hMPM.
Fichier principal
Vignette du fichier
Deep_dive_into_the_immune_response_against_murine_.pdf (9.22 Mo) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

inserm-03936253 , version 1 (12-01-2023)

Identifiants

Citer

Esther Stern, Stefano Caruso, Clément Meiller, Inbal Mishalian, Theo Hirsch, et al.. Deep dive into the immune response against murine mesothelioma permits design of novel anti-mesothelioma therapeutics. Frontiers in Immunology, 2023, 13, pp.1026185. ⟨10.3389/fimmu.2022.1026185⟩. ⟨inserm-03936253⟩
39 Consultations
32 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More